Phase II Multicenter Study Evaluating the Tolerability and Efficacy of RAD001 (Everolimus) in Patients With Relapsed or Metastatic Endometrial Cancer
- Estimate the rate of non-progression after 3 months of treatment with everolimus in
patients with relapsed or metastatic endometrial cancer.
- Evaluate the partial and complete response rate after 3 months of treatment with
everolimus in these patients.
- Evaluate the duration of response in these patients.
- Evaluate the clinical benefit after 6 months of treatment with everolimus in these
- Evaluate the time to progression in these patients.
- Evaluate the progression-free and overall survival of these patients.
- Evaluate the nature, frequency, and severity of side effects of everolimus in these
OUTLINE: This is a multicenter study.
Patients receive oral everolimus daily in the absence of disease progression or unacceptable
After completion of study treatment, patients are followed monthly for 3 months and then
every 3 months thereafter.
Allocation: Non-Randomized, Primary Purpose: Treatment
Rate of non-progression after 3 months of treatment with everolimus as assessed by RECIST criteria
Laure Chauvenet, MD
Hotel Dieu de Paris
United States: Federal Government